Belite Bio Inc ADR (BLTE)

Nov 27, 2024, 3:00 AM EST - 7 weeks ago

Lin BioScience Receives U.S. FDA Fast Track Designation For LBS-007

Nov 12, 2024, 8:28 PM EST - 2 months ago

Belite Bio, Inc. (BLTE) Q3 2024 Earnings Call Transcript

Nov 5, 2024, 8:00 AM EST - 2 months ago

Belite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial Results

Nov 3, 2024, 4:00 PM EST - 2 months ago

Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds

Sep 1, 2024, 8:00 AM EDT - 4 months ago

Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer

Aug 12, 2024, 10:35 PM EDT - 5 months ago

Belite Bio, Inc (BLTE) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 4:30 PM EDT - 5 months ago

Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

Aug 8, 2024, 8:00 AM EDT - 5 months ago

Belite Bio to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Aug 5, 2024, 7:10 PM EDT - 5 months ago

Belite Bio to Host Webcast on August 12, 2024, to Discuss Second Quarter 2024 Financial Results

Jun 12, 2024, 2:55 AM EDT - 7 months ago

Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan

May 14, 2024, 8:11 PM EDT - 8 months ago

Belite Bio, Inc (BLTE) Q1 2024 Earnings Call Transcript

May 14, 2024, 8:00 AM EDT - 8 months ago

Belite Bio to Participate in the Benchmark's 4th Annual Healthcare House Call Investor Conference

May 13, 2024, 9:50 PM EDT - 8 months ago

Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update

May 13, 2024, 8:00 AM EDT - 8 months ago

Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

May 8, 2024, 8:00 AM EDT - 9 months ago

Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results

May 6, 2024, 8:15 AM EDT - 9 months ago

Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On Tinlarebant

May 6, 2024, 8:00 AM EDT - 9 months ago

Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting

May 1, 2024, 4:15 PM EDT - 9 months ago

Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting

Apr 25, 2024, 7:15 PM EDT - 9 months ago

Belite Bio Announces $25 Million Registered Direct Offering

Mar 22, 2024, 8:00 AM EDT - 10 months ago

Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan

Mar 12, 2024, 7:53 PM EDT - 11 months ago

Belite Bio, Inc (BLTE) Q4 2023 Earnings Call Transcript

Mar 11, 2024, 10:28 PM EDT - 11 months ago

Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website

Mar 11, 2024, 9:27 PM EDT - 11 months ago

Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Mar 6, 2024, 8:00 AM EST - 11 months ago

Belite Bio to Host Webcast on March 12, 2024, to Discuss Fourth Quarter and Full Year 2024 Financial Results

Mar 4, 2024, 8:00 AM EST - 11 months ago

Belite Bio to Participate in the Leerink Partners Global Biopharma Conference

Feb 7, 2024, 8:00 AM EST - 1 year ago

Belite Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Nov 30, 2023, 8:00 AM EST - 1 year ago

Belite Bio to Participate in the Benchmark Company's Upcoming Discovery One-on-One Investor Conference

Nov 20, 2023, 8:00 AM EST - 1 year ago

Belite Bio to Participate in the BTIG Ophthalmology Day

Nov 14, 2023, 11:30 PM EST - 1 year ago

Belite Bio, Inc (BLTE) Q3 2023 Earnings Call Transcript

Nov 13, 2023, 8:15 PM EST - 1 year ago

Belite Bio Reports Third Quarter 2023 Operational Highlights and Financial Results

Nov 7, 2023, 8:00 AM EST - 1 year ago

Belite Bio to Host Webcast on November 14, 2023, to Discuss Third Quarter 2023 Financial Results

Nov 6, 2023, 8:00 AM EST - 1 year ago

Belite Bio Presents Results from a 24-month, Phase 2 Study of Tinlarebant in Childhood-onset Stargardt Disease at the AAO Annual Meeting

Oct 27, 2023, 8:00 AM EDT - 1 year ago

Belite Bio Announces Presentation at the American Academy of Ophthalmology 2023 Annual Meeting

Aug 22, 2023, 3:51 PM EDT - 1 year ago

Belite Bio: The Pick Of The Post-IPO Biotechs - Is There Further Upside Ahead?

Aug 13, 2023, 9:45 AM EDT - 1 year ago

Belite Bio, Inc (BLTE) Q2 2023 Earnings Call Transcript

Aug 8, 2023, 10:17 PM EDT - 1 year ago

Belite Bio Reports Second Quarter 2023 Operational Highlights and Financial Results

Aug 4, 2023, 8:00 AM EDT - 1 year ago

Belite Bio to Host Webcast on August 9, 2023 to Discuss Second Quarter 2023 Financial Results

Jul 27, 2023, 5:00 PM EDT - 1 year ago

Belite Bio Doses First Subject in Pivotal Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant for GA

Jul 24, 2023, 6:04 AM EDT - 1 year ago

Belite Bio Completes Enrollment in Pivotal Global Phase 3 DRAGON Trial Evaluating Oral Tinlarebant for Stargardt Disease

Jun 15, 2023, 12:34 PM EDT - 1 year ago

Belite Bio: Undercovered Eye Disease Company With Early Data

Jun 9, 2023, 8:40 AM EDT - 1 year ago

Top 5 Health Care Stocks That Are Set To Fly In Q2

CLPT COO IRTC STAA

May 30, 2023, 8:49 PM EDT - 1 year ago

Belite Bio Announces Pricing of $30 Million Underwritten Public Offering of American Depositary Shares and Warrants

May 30, 2023, 4:01 PM EDT - 1 year ago

Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares and Warrants

May 14, 2023, 4:42 AM EDT - 1 year ago

Belite Bio, Inc (BLTE) Q1 2023 Earnings Call Transcript

May 10, 2023, 7:58 PM EDT - 1 year ago

Belite Bio Reports First-Quarter 2023 Operational Highlights and Financial Results

May 10, 2023, 3:33 PM EDT - 1 year ago

Belite Bio to Host Webcast on May 11, 2023 to Discuss First Quarter 2023 Financial Results

May 4, 2023, 11:09 AM EDT - 1 year ago

Belite Bio to Host Key Opinion Leader Webinar Discussing Progression of Childhood-onset STGD1 and Relevance of the Tinlarebant 18-month Phase 2 Data

Apr 25, 2023, 4:30 PM EDT - 1 year ago

Belite Bio Presented 18-Month Interim Data from a 24-Month Phase 2 Study of Tinlarebant in Adolescent Stargardt Disease at the 2023 ARVO Meeting

Apr 11, 2023, 9:00 AM EDT - 1 year ago

Belite Bio to Host Key Opinion Leader Webinar on RBP4 Antagonist Tinlarebant in Late-Stage Development for Stargardt Disease 1

Apr 3, 2023, 8:39 PM EDT - 1 year ago

Belite Bio, Inc (BLTE) Q4 2022 Earnings Call Transcript